Dr. Lara A. Dunn, MD

  • New York, NY
  • Medical oncologist
NPI1740416197PAC ID6800037326
Medicare services, 2024
594
Medicare patients, 2024
164
Part D claims, 2024
648
Publications
66
Clinical trials
7
Practice address
1275 York Avenue, New York, NY 10065
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Primary practice

Memorial Sloan Kettering Cancer Center

Hospital · New York, New York

See all 4 affiliations

Find Dr. Dunn's professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. Lara A. Dunn is a medical oncologist in New York, New York

Dr. Dunn practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Dunn's NPI, 1740416197, was assigned on May 29, 2009. Dr. Dunn graduated from Perelman School of Medicine - Philadelphia in 2009. Dr. Dunn holds New York license 262228.

NPI and contact details
Medicare PAC ID
6800037326
NPI enumeration date
May 29, 2009
NPI status
Active
Accepts Medicare assignment
Yes
Offers telehealth
Yes
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Female
Estimated age
43
Medical school graduation
2009

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)

Dr. Lara A. Dunn practices at Memorial Sloan Kettering Cancer Center in New York, New York

Dr. Dunn's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Source: Dmand AI Affiliation Data

Dr. Lara A. Dunn is affiliated with 2 sites of care and 2 medical groups

Dr. Dunn's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Dunn to 1 more home health agency and 1 medical group, each named with a free account.

See all 4 affiliations for Dr. Dunn

Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data

Dmand AI tracks the EHR system at Dr. Lara A. Dunn's practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dunn practices, 2 sites in all. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
Memorial Sloan Kettering Cancer CenterAvailable with a free account
+1 more site and 1 medical groupAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every hospital where Dr. Dunn practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.

Dr. Lara A. Dunn is one of 458 medical oncologists in New York

Medical oncology is Dr. Dunn's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dunn is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Dunn's licenses on file in 3 states: New York, Florida and New Jersey.

Specialties and state licenses

  • Medical oncology, New YorkPrimaryLicense 262228 · 2011 to 2026 · taxonomy 207RX0202X
  • Florida licenseSince 2021
  • New Jersey license2019 to 2025

Clinical focus

Dmand AI lists chronic leukemia and lymphoma among the conditions Dr. Dunn treats.

Medical oncologists near Dr. Dunn

Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. Lara A. Dunn billed Medicare for 594 services in 2024

CMS data shows 594 Medicare services from Dr. Dunn across 4 procedure codes in 2024, for 164 Medicare patients. Medicare paid $63,009 for them. Every service was in an office.

Medicare services, 2024594
Medicare patients164
Paid by Medicare$63,009
Procedure codes4

Dr. Dunn's Medicare services by type, 2023 to 2024

  • 2023
  • 2024
Office and hospital visits
2023: 5002024: 59419%
Other services
2023: 322024: 0100%

Dr. Dunn compared with the New York median for medical oncologists, 2024

  • Dr. Dunn
  • New York median
Medicare services
594vs 34075% above
Medicare patients
164vs 11246% above
Part D claims
439vs 1303.4 times

Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.

Dr. Dunn's most billed Medicare procedure codes, 2024

CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.

See all procedures by Dr. Dunn

Need commercial claims for Dr. Dunn?

Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Dunn and other medical oncologists in New York.

Book a meeting

Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks

Dr. Lara A. Dunn treated 164 Medicare patients in 2024, average age 74

CMS counts 164 Medicare patients who saw Dr. Dunn in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dunn's median patient age at 72, with 26% women.

Medicare patients, 2024164
Average age74
Average risk score2.32
Also on Medicaid14%

Dr. Dunn's Medicare patients by age, 2024

Dr. Dunn's Medicare patients by sex, 2024

  • Women4829%
  • Men11671%

Chronic conditions among Dr. Dunn's Medicare patients, 2024

  1. High cholesterol75%
  2. High blood pressure73%
  3. Arthritis45%
  4. Anxiety35%
  5. Diabetes32%
  6. Ischemic heart disease30%
  7. Cancer27%
  8. Chronic kidney disease23%

Share of Medicare patients with each condition. A patient can have several.

Dr. Dunn's patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 72

Patient panel by sex, all payers

  • Women26%
  • Men72%

Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data

Dr. Lara A. Dunn wrote 648 Medicare Part D claims in 2024

In 2024, Dr. Dunn wrote 648 Medicare Part D claims for 99 patients. 88% of them were for generic drugs. CMS names the drug for 439 of them, across 17 drugs with 11 or more claims each, at $10,450 in total drug cost. In 2023, CMS named 311 claims across 13 drugs.

Part D claims, 2024648
Drugs named by CMS17
Total drug cost$10,450
Part D patients99

Dr. Dunn's Part D claims by kind of drug, 2024

  • Generic573 claims88%
  • Brand-name and other75 claims12%

Dr. Dunn's most prescribed drugs by claims, 2024

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Drug classes CMS tracks in Dr. Dunn's Part D claims, 2024

  • Opioids26%168 of 648 claims
  • Antibiotics4%27 of 648 claims
  • Antipsychotics, patients 65 and over3%17 of 648 claims

Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.

Part D claims for drugs CMS names, 2023 to 2024

  • 2023
  • 2024
Claims for drugs CMS names
2023: 3112024: 43941%

Drugs named by CMS: 17 in 2024, 13 in 2023.

See all prescribing by Dr. Dunn

Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data

Dr. Lara A. Dunn scored 76 out of 100 in Medicare's MIPS program for 2024

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Dunn for performance year 2024, reported as part of a group. Dr. Dunn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dunn as offering telehealth.

Accepts Medicare assignment
Yes
Offers telehealth
Yes

Dr. Dunn's MIPS scores, performance year 2024

  • 76of 100Final score
  • 60.6of 100Quality
  • 40of 100Improvement Activities
  • 74of 100Cost

Each score is out of 100. The final score weighs the categories CMS scored for this clinician.

Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026

For MedTech and pharma teams

Find medical oncologists like Dr. Dunn by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. Lara A. Dunn has 66 publications on record

Dmand AI links 66 papers to Dr. Dunn, published from 2015 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Squamous Cell Carcinoma of Head and Neck. Dr. Dunn has published most often in Oral Oncol. Dr. Dunn's most frequent co-authors are Nadeem Riaz, MD, David G. Pfister, MD and Yao Yu, MD.

Papers66
Years published2015 to 2025

Dr. Dunn's papers by year, 2016 to 2025

Topics Dr. Dunn writes about most

  • Head and Neck Neoplasms
  • Carcinoma, Squamous Cell
  • Squamous Cell Carcinoma of Head and Neck
  • Antineoplastic Agents
  • Chemoradiotherapy
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma
  • Oropharyngeal Neoplasms

Dr. Dunn's most frequent co-authors

Recent publications by Dr. Dunn

See all 66 publications and co-authors

See who Dr. Dunn researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Dunn works with, so you can find a warm path to the right medical oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. Lara A. Dunn has worked on 7 clinical trials

Dmand AI links Dr. Dunn to 7 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck and Adenocarcinoma, Sebaceous. Memorial Sloan Kettering Cancer Center sponsors the most, 4. Open Payments lists research payments to Dr. Dunn that name 1 trial.

Clinical trials with Dr. Dunn by phase

  1. 3Phase 1: 3 trials
  2. 4Phase 2: 4 trials
  3. NonePhase 3: no trials
  4. NonePhase 4: no trials

Conditions in Dr. Dunn's trials

  • Carcinoma, Squamous Cell
  • Squamous Cell Carcinoma of Head and Neck
  • Adenocarcinoma, Sebaceous
  • Head and Neck Neoplasms
  • Neoplasms, Squamous Cell

Investigators on the most trials with Dr. Dunn

Recent clinical trials with Dr. Dunn

See all 7 clinical trials and co-investigators

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. Lara A. Dunn received $46,129 in industry payments from 2017 to 2025

CMS Open Payments shows 64 general payments to Dr. Dunn from 5 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 85% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $38,261. It also lists 89 research payments totaling $11,444 from 2018 to 2024, naming 1 clinical trial.

General payments to Dr. Dunn by program year, 2017 to 2025

General payments to Dr. Dunn by kind, 2017 to 2025

$46.1Kin total
  • Consulting fees$39,14785%
  • Travel and lodging$5,55812%
  • Food and beverage$1,4243%

Companies that paid Dr. Dunn the most, 2017 to 2025

Share is of all general payments to this clinician.

See all payments to Dr. Dunn

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. Lara A. Dunn graduated from Perelman School of Medicine - Philadelphia

Dr. Dunn graduated from Perelman School of Medicine - Philadelphia in 2009. Dr. Dunn is a member of ASCO.

  1. Medical schoolPerelman School of Medicine - Philadelphia
  2. Board certified in medical oncologyAmerican Board of Internal Medicine

Source: Dmand AI Professional Profile Data

Dr. Lara A. Dunn accepts plans from 13 insurance carriers

Dr. Dunn is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.

  • Aetna
  • Blue Cross Blue Shield of Michigan
  • Excellus BlueCross BlueShield
  • United Healthcare
  • Blue Cross Blue Shield of Massachusetts
  • HCSC
  • MVP Health Care
  • Aspirus Health Plan
  • +5 more carriersWith a free account

Plan types Dr. Dunn accepts, by number of carriers

  1. PPO9
  2. Medicare7
  3. EPO4
  4. HMO4
  5. POS4
  6. Medicaid1

Source: Dmand AI Insurance Network Data

Sources for Dr. Lara A. Dunn's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneDmand AI Affiliation Data
Primary practice, affiliations and health systemDmand AI Affiliation DataDmand AI Org Hierarchy Data
Medicare services and procedure codesMedicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab)
State medians for the same specialtyDmand AI Peer Benchmarks
Medicare patients and the all-payer patient panelDmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab)
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab)
MIPS scores, telehealth, assignment and procedure percentilesDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigatorsDmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Training, board certification and membershipsDmand AI Professional Profile Data
Insurance carriers and plan typesDmand AI Insurance Network Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. Lara A. Dunn

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. Lara A. Dunn's NPI number?

Dr. Lara A. Dunn's NPI number is 1740416197. It was assigned on May 29, 2009, and it is active in the NPI Registry.

What kind of doctor is Dr. Lara A. Dunn?

Dr. Lara A. Dunn is a medical oncologist in New York, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).

Where does Dr. Lara A. Dunn practice?

Dr. Dunn practices at 1275 York Avenue, New York, NY 10065. Dr. Dunn's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Dunn to 1 home health agency and 1 medical group.

What is Dr. Lara A. Dunn's medical license number?

Dr. Dunn holds New York license 262228, one of the licenses on file in 3 states.

Which states has Dr. Lara A. Dunn been licensed in?

Dmand AI has state licenses on file for Dr. Dunn in New York (2011 to 2026), Florida (since 2021) and New Jersey (2019 to 2025).

Which hospitals is Dr. Lara A. Dunn affiliated with?

Dr. Dunn practices at Memorial Sloan Kettering Cancer Center in New York, New York.

What medical group is Dr. Lara A. Dunn part of?

Dr. Dunn is linked to Memorial Sloan Kettering Cancer Center. Dmand AI links Dr. Dunn to 1 more medical group.

Does Dr. Lara A. Dunn accept Medicare?

Yes. CMS data shows Dr. Dunn billed Medicare for 594 services in 2024, and Dr. Dunn accepts Medicare assignment.

Does Dr. Lara A. Dunn offer telehealth?

Yes. The CMS Doctors and Clinicians file lists Dr. Dunn as offering telehealth services.

What is Dr. Lara A. Dunn's MIPS score?

Dr. Dunn's MIPS final score for performance year 2024 is 76 out of 100, reported as part of a group.

Show 10 more questionsShow fewer questions

How many Medicare patients does Dr. Lara A. Dunn see?

CMS counts 164 Medicare patients who saw Dr. Dunn in 2024, with an average age of 74.

Is Dr. Lara A. Dunn board certified?

Yes. Dr. Dunn is board certified in medical oncology by the American Board of Internal Medicine.

What services does Dr. Lara A. Dunn bill to Medicare?

In 2024, Dr. Dunn's most billed Medicare services were office visit, established patient (99214), office visit, established patient (99215) and office visit, new patient (99205).

Where did Dr. Lara A. Dunn go to medical school?

Dr. Dunn graduated from Perelman School of Medicine - Philadelphia in 2009.

What drugs does Dr. Lara A. Dunn prescribe most?

In 2024 Medicare Part D data, Dr. Dunn's most prescribed drugs by claims were Fentanyl, Oxycodone HCl and Levothyroxine Sodium.

Has Dr. Lara A. Dunn received payments from drug or device companies?

CMS Open Payments shows $46,129 in general payments to Dr. Dunn from 5 companies from 2017 to 2025. The largest total came from Regeneron Pharmaceuticals, Inc.

How long has Dr. Lara A. Dunn been practicing?

Dr. Dunn graduated from medical school in 2009, 17 years ago.

Does Dr. Lara A. Dunn do research?

Dmand AI links 66 publications to Dr. Dunn, published from 2015 to 2025. Dr. Dunn has worked on 7 clinical trials.

Who does Dr. Lara A. Dunn publish with?

Dr. Dunn's most frequent co-authors are Nadeem Riaz, MD (26 shared papers), David G. Pfister, MD (25 shared papers) and Yao Yu, MD (23 shared papers).

What insurance does Dr. Lara A. Dunn accept?

Dr. Dunn is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.

Selling to medical oncology practices?

See medical oncologists in New York by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)